JP2020534289A - がんの治療のための方法および組成物 - Google Patents

がんの治療のための方法および組成物 Download PDF

Info

Publication number
JP2020534289A
JP2020534289A JP2020515740A JP2020515740A JP2020534289A JP 2020534289 A JP2020534289 A JP 2020534289A JP 2020515740 A JP2020515740 A JP 2020515740A JP 2020515740 A JP2020515740 A JP 2020515740A JP 2020534289 A JP2020534289 A JP 2020534289A
Authority
JP
Japan
Prior art keywords
ido1
inhibitor
cancer
agent
angiogenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020515740A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020534289A5 (https=
Inventor
ミュラー、アレクサンダー、ジェイ．
モンダル、アルピタ
デイ、スーヴィック
プレンダーガスト、ジョージ、シー．
Original Assignee
ランケナー インスティテュート フォー メディカル リサーチ
ランケナー インスティテュート フォー メディカル リサーチ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ランケナー インスティテュート フォー メディカル リサーチ, ランケナー インスティテュート フォー メディカル リサーチ filed Critical ランケナー インスティテュート フォー メディカル リサーチ
Publication of JP2020534289A publication Critical patent/JP2020534289A/ja
Publication of JP2020534289A5 publication Critical patent/JP2020534289A5/ja
Priority to JP2023193160A priority Critical patent/JP2024023290A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2020515740A 2017-09-14 2018-09-14 がんの治療のための方法および組成物 Pending JP2020534289A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023193160A JP2024023290A (ja) 2017-09-14 2023-11-13 がんの治療のための方法および組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762558573P 2017-09-14 2017-09-14
US62/558,573 2017-09-14
PCT/US2018/051088 WO2019055786A1 (en) 2017-09-14 2018-09-14 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023193160A Division JP2024023290A (ja) 2017-09-14 2023-11-13 がんの治療のための方法および組成物

Publications (2)

Publication Number Publication Date
JP2020534289A true JP2020534289A (ja) 2020-11-26
JP2020534289A5 JP2020534289A5 (https=) 2021-10-28

Family

ID=65724068

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020515740A Pending JP2020534289A (ja) 2017-09-14 2018-09-14 がんの治療のための方法および組成物
JP2023193160A Pending JP2024023290A (ja) 2017-09-14 2023-11-13 がんの治療のための方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023193160A Pending JP2024023290A (ja) 2017-09-14 2023-11-13 がんの治療のための方法および組成物

Country Status (5)

Country Link
US (2) US20200261414A1 (https=)
EP (2) EP4176876A1 (https=)
JP (2) JP2020534289A (https=)
ES (1) ES2935729T3 (https=)
WO (1) WO2019055786A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240084002A1 (en) * 2020-12-07 2024-03-14 Lankenau Institute For Medical Research Methods and compositions utilizing ido1-dependent vascularizing cells for the treatment of pathological conditions involving neovascularization
WO2023025312A1 (zh) 2021-08-27 2023-03-02 深圳艾欣达伟医药科技有限公司 使用th-302治疗parp抑制剂耐药的患者
CN117651548B (zh) 2021-08-27 2026-03-03 深圳艾欣达伟医药科技有限公司 冻干制剂溶液及冻干制剂、方法和用途
US20250186468A1 (en) 2022-03-15 2025-06-12 Ascentawits Pharmaceuticals, Ltd. Method for treating patient with brca-mutated cancer
CN119384281A (zh) 2022-04-15 2025-01-28 深圳艾欣达伟医药科技有限公司 使用th-302单药或联用parp抑制剂治疗癌症的方法
CN119233822A (zh) 2022-05-23 2024-12-31 深圳艾欣达伟医药科技有限公司 烷化剂前药与细胞周期抑制剂联用治疗癌症的方法
CN119894521A (zh) 2022-09-22 2025-04-25 深圳艾欣达伟医药科技有限公司 乏氧激活的化合物在制备治疗癌症患者的药物中的用途
KR20250160163A (ko) 2023-02-27 2025-11-11 아센타위츠 파마슈티컬즈 리미티드 용액, 동결건조 제형, 동결건조 제형 단위 패키지, 주사제, 및 주사제 제조 방법
WO2025026214A1 (zh) 2023-07-28 2025-02-06 深圳艾欣达伟医药科技有限公司 治疗p53基因突变或缺陷阴性癌症、肿瘤患者

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017062354A1 (en) * 2015-10-05 2017-04-13 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors and immuno-oncology agents

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050032733A1 (en) 2001-05-18 2005-02-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA)
US7714139B2 (en) 2003-03-27 2010-05-11 Lankenau Institute For Medcial Research IDO inhibitors and methods of use
ZA200507752B (en) * 2003-03-28 2007-01-31 Threshold Pharmaceuticals Inc Compositions and methods for treating cancer
PL1879573T3 (pl) 2005-05-10 2013-05-31 Incyte Holdings Corp Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania
US7705022B2 (en) 2005-10-27 2010-04-27 Lankenau Institute For Medical Research IDO inhibitors and methods of use thereof
US8450351B2 (en) 2005-12-20 2013-05-28 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
US20080146624A1 (en) 2006-09-19 2008-06-19 Incyte Corporation Amidines as modulators of indoleamine 2,3-dioxygenase
WO2008036643A2 (en) 2006-09-19 2008-03-27 Incyte Corporation Amidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
WO2008058178A1 (en) 2006-11-08 2008-05-15 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
CA2706378C (en) 2007-11-20 2017-09-12 Lankenau Institute For Medical Research Disulfide chemotherapeutic agents and methods of use thereof
JP5465720B2 (ja) 2008-07-08 2014-04-09 インサイト・コーポレイション インドールアミン２，３−ジオキシゲナーゼの阻害剤としての１，２，５−オキサジアゾール
NO2694640T3 (https=) 2011-04-15 2018-03-17
AU2013204313C1 (en) * 2012-06-01 2016-04-07 Bionomics Limited Combination Therapy
WO2016090174A1 (en) * 2014-12-03 2016-06-09 Auckland Uniservices, Ltd. Kinase inhibitor prodrug for the treatment of cancer
EP4659747A2 (en) 2015-07-24 2025-12-10 Lumos Pharma, Inc. Salts and prodrugs of 1-methyl-d-tryptophan
US20190241573A1 (en) * 2016-07-20 2019-08-08 Glaxosmithkline Intellectual Property Development Limited Isoquinoline derivatives as perk inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017062354A1 (en) * 2015-10-05 2017-04-13 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors and immuno-oncology agents

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BRITISH JOURNAL OF CANCER, vol. Vol.85, No.6, pp.881-890, JPN6022043072, 2001, ISSN: 0004898351 *
CANCER BIOLOGY & THERAPY, vol. Vol.17, No.4, pp.371-380, JPN6022043076, 2016, ISSN: 0005104095 *
CANCER RES, vol. Vol.73, No.6, pp.1993-2002, JPN6022043074, 2013, ISSN: 0005104096 *
INTERNATIONAL JOURNAL OF ONCOLOGY, vol. Vol.38, No.1, pp.113-120, JPN6022043075, 2011, ISSN: 0005104097 *
ONCOTARGET, vol. Vol.7, No.7, pp.7372-7380, JPN6022043073, 2016, ISSN: 0004898352 *
PNAS, vol. Vol.101, No.9, pp.3130-3135, JPN6022043071, 2004, ISSN: 0004898349 *

Also Published As

Publication number Publication date
WO2019055786A1 (en) 2019-03-21
ES2935729T3 (es) 2023-03-09
US20240374566A1 (en) 2024-11-14
US20200261414A1 (en) 2020-08-20
EP4176876A1 (en) 2023-05-10
EP3681498B1 (en) 2022-10-05
EP3681498A4 (en) 2021-06-02
EP3681498A1 (en) 2020-07-22
JP2024023290A (ja) 2024-02-21

Similar Documents

Publication Publication Date Title
US20240374566A1 (en) Methods and compositions for the treatment of cancer
KR20220061974A (ko) Smarca2/4 저하제에 대한 반응체 확인 방법
CN118459413A (zh) 用于治疗癌症的组合物和方法
JP6797027B2 (ja) メタドヘリン−ｓｎｄ１相互作用を遮断するペプチドの癌の治療としての使用
JP2018513123A (ja) Ｒｏｒガンマ阻害剤を用いてがんを治療するための方法
CN107530433A (zh) 针对具有braf基因突变的细胞的细胞死亡诱导试剂、该细胞的增殖抑制试剂及用于治疗由该细胞的增殖异常导致的疾病的医药组合物
US20240398804A1 (en) Methods of treating cancer having an active wnt/beta-catenin pathway
EP3289104B1 (en) Method for treating high-grade gliomas
US20230100102A1 (en) Cxcr7 inhibitors for the treatment of cancer
JP2017527615A (ja) 線維化疾患及び癌を治療するための組成物及び方法
US20240408071A1 (en) Novel combination of serotonin receptor (5-htr2b) antagonist and an immunomodulator and chemotherapeutic drugs for inhibition of cancer
US20200023038A1 (en) Method of treating neoplasias
JP7365694B2 (ja) 抗腫瘍免疫療法増強剤
US20250281609A1 (en) Composition for treating or preventing cancer
US20210023107A1 (en) USE OF 6-THIO-dG TO TREAT THERAPY-RESISTANT TELOMERASEPOSITIVE PEDIATRIC BRAIN TUMORS
HK40093210A (en) Methods and compositions for the treatment of cancer
AU2021279243A1 (en) New therapy for the treatment of tumors
US20220125770A1 (en) Combination therapy of alk-positive neoplasia
US20220347180A1 (en) Enhancing cancer therapy treatment with bh3 mimetics
CN116271056A (zh) 针对具有braf基因突变的细胞的细胞死亡诱导试剂、该细胞的增殖抑制试剂及用于治疗由该细胞的增殖异常导致的疾病的医药组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210914

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210914

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211007

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221018

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230117

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230317

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230418

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230419

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230711